Format

Send to

Choose Destination
Curr Opin Pharmacol. 2005 Aug;5(4):382-7.

Arming antibodies for cancer therapy.

Author information

1
Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA. ppolakis@gene.com

Abstract

Specifying the delivery of a highly toxic agent to cancers while sparing normal tissue is an attractive prospect for the treatment of cancer. Cell surface antigens with highly restricted expression patterns have been identified and the means by which cytotoxic agents are appended to antibodies has been greatly refined. Myriad formulations involving radionuclides, bacterial toxins and small-molecule drugs linked to antibodies through peptides, protein fusions and chelating agents are in preclinical and clinical evaluation, and a few have been approved as human medicines. Recent advances hold promise for improving the therapeutic index of these anti-cancer drugs.

PMID:
15951239
DOI:
10.1016/j.coph.2005.04.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center